Agenus earnings beat by $0.08, revenue topped estimates

Agenus (AGEN) reported Q3 EPS of -$0.18, beating estimates by $0.08, with revenue of $33.7M, exceeding expectations of $28.23M. The stock is up 0.14% in 3 months and 75.52% in 12 months. InvestingPro rates its financial health as 'good performance'.

Original reporting
Published Nov 5, 2026, 3:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AGEN
Bullish
medium confidence
Mentioned
$AGEN
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

Earnings surprise could trigger short‑term buying interest, but the modest size limits broader market effect.

02

Market read

The earnings beat provides a modest trading catalyst for AGEN.

03

What to watch

No forward guidance was provided, and cash burn remains high.

Relevance 6/10Novelty 6/10Timing: post‑earnings today

Background

Agenus (NASDAQ: AGEN) is a clinical‑stage immunotherapy company. The article reports its Q3 earnings beat.

Company-level read

Ticker impact

$AGENBullishMedium confidence
Context

Agenus reported Q3 EPS of -$0.18 beating the estimate by $0.08 and revenue of $33.7M versus $28.23M consensus.

Expected impact

likely modest upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat is modest but improves outlook; investors may buy on the surprise.

Market effects

Biotech small‑cap earnings may influence peer sentiment in the oncology space.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

The beat is small and may not translate into sustained price gains; watch for guidance.

Key entities

  • Agenus

    Biotech firm reporting Q3 results.

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.